T10583 |
Bosutinib D8
|
T10583
|
98%
|
|
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
|
T77969 |
SIAIS100 TFA
|
|
98%
|
|
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
|
T79716 |
C-ABL-IN-5
|
|
98%
|
|
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabo...
|
T82909 |
BCR-ABL-IN-8
|
1808288-49-4
|
98%
|
|
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].
|
T14925 |
Cenisertib
|
871357-89-0
|
98%
|
|
Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well a...
|
T10488 |
BCR-ABL-IN-1
|
188260-50-6
|
98%
|
|
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
|
T12907 |
SIAIS178
|
2376047-73-1
|
98%
|
|
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
|
T22303 |
Dasatinib hydrochloride
|
854001-07-3
|
99.98%
|
|
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent ant...
|
T11960 |
MBM-55
|
2083622-09-5
|
99.98%
|
|
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing...
|
T6300 |
Degrasyn
|
856243-80-6
|
99.98%
|
|
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (...
|
T8882 |
Vodobatinib
|
1388803-90-4
|
99.93%
|
|
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
|
T2609 |
Masitinib
|
790299-79-5
|
99.91%
|
|
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 200...
|
T1448L |
Dasatinib monohydrate
|
863127-77-9
|
99.89%
|
|
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
|
T1448 |
Dasatinib
|
302962-49-8
|
99.89%
|
|
Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitum...
|
T12310 |
ON 146040
|
1404231-34-0
|
99.89%
|
|
ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.
|
T2341 |
KW-2449
|
1000669-72-6
|
99.89%
|
|
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
|
T3068 |
AT9283
|
896466-04-9
|
99.87%
|
|
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
|
T10800 |
CHMFL-ABL-121
|
2270879-07-5
|
99.86%
|
|
CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein).
|
T34656 |
SKLB 1028
|
1350544-93-2
|
99.85%
|
|
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
|
T0152 |
Bosutinib
|
380843-75-4
|
99.84%
|
|
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
|